ADBrain™ – Alzheimer’s Disease Model
ADBrain™ extends the RealBrain® platform into disease modelling. In just three weeks, human iPSC-derived neural tissues develop hallmark features of sporadic Alzheimer’s disease: amyloid accumulation, tau phosphorylation, disrupted networks, and neuroinflammation. Tessara offers this model as a service to help you quantify pathology and therapeutic rescue in a clinically relevant context.
Amyloid Deposition (green)
Loss of neural connection
Neurofibrillary tangles
RealBrain® Platform
Why ADBrain™
Alzheimer’s research has been slowed by models that lack reproducibility and translational value. ADBrain™ closes this gap, enabling measurable pathology and functional rescue in a standardised, assay-ready format. It allows you to test drugs in a system that mirrors human disease biology — and to generate data that stand up in decision-making.
Neurons and astrocytes naturally derived from the same population of human iPSCs engineered to develop Alzheimer’s-like pathology — a disease-relevant cellular environment.
Aβ42 accumulation and elevated pTau — key biomarkers aligned with clinical pathology.
Neurite loss and reduced network connectivity — quantifiable morphological disruption.
Single tissue per well — reproducible data across plates and studies.
High-throughput ready — compatible with 96- and 384*-well formats for scalable screening.
Broad assay compatibility
Key Features
ADBrain™
What You Can Do With It
ADBrain™
ADBrain™ is fully compatible with any assay platform — allowing you to measure amyloid, tau, inflammation, and functional rescue with the same tools you already rely on. Tessara offers ADBrain™ as a service, providing comprehensive screening and mechanistic studies in a reproducible Alzheimer’s model.
Our ADBrain™ Services offering includes:
Efficacy Screening – rank compounds by their ability to rescue AD-relevant phenotypes; multiparametric assays
Safety & Cytotoxicity Profiling – acute and chronic neurotoxicity, oxidative stress assays (ROS-Glo® H₂O₂), LDH and viability testing.
Neuroinflammation Studies – GFAP imaging, cytokine and chemokine multiplex profiling, glial activation markers.
Target Validation & Disease Biomarkers – Aβ42, total tau, pTau isoforms (181, 217, 231), Nf-L, synaptic proteins.
Neurodegeneration & Cell Death Mechanisms – ferroptosis pathway assays, neuronal loss visualised via confocal and brightfield imaging.
Neural Network Analysis – quantify connectivity and neurite complexity with confocal imaging.
Biomarker Discovery – integrated omics profiling to identify translational signatures of efficacy and mechanism.
Custom Study Design – tailored assay panels and dosing regimens to fit your pipeline.
ADBrain™: From Pathology to Rescue - reproducible, disease-relevant, and clinically aligned.
ADBrain™ provides the translational data needed to de-risk Alzheimer’s programs, prioritise the right drug candidates, and accelerate discovery decisions.